FDA Approves New Administration Method for Tecentriq (atezolizumab)

2024-09-16T16:06:41-05:00September 16th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that [...]

Why Low-Dose Lung Cancer Screening Should Be Routine

2024-07-03T07:54:16-05:00July 1st, 2024|Hot Topics, Newsletter Articles, Small Cell Lung Cancer Spotlight, Spotlights, Survivors, Women, Your Community|

Low-dose CT scans for lung cancer should be as routine as mammograms  Estela Mara Bensimon is a university professor emerita at the University of Southern California and the founder of the Center for Urban Education, whose mission is to [...]

FDA Approves Augtyro (repotrectinib) for Adults and Children with NTRK-Positive Solid Tumors

2024-07-02T15:52:49-05:00June 14th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]

Go to Top